Zenova Bio was founded on one thesis: that the research peptide market needed a supplier willing to do the work that pharmaceutical manufacturers do — and publish the results for anyone to examine.
Every decision at Zenova Bio — from the testing protocol we run to the labs we partner with — flows from three principles that have been consistent since we synthesized our first batch in 2019.
Every lot report is published in full — not a summary, not a one-line purity percentage. We publish the raw chromatogram, the mass spec data, the endotoxin reading, the heavy metals panel. If we can't show you the proof, we don't ship the lot.
Pharmaceutical-grade isn't a marketing claim — it's a specification. Our 99% minimum purity threshold, <0.05 EU/mg endotoxin limit, and cGMP synthesis environment are verified by independent laboratories that have no commercial incentive to pass our product.
We sell research peptides. We do not manufacture therapeutic drugs, and we do not market our products as such. The compliance banner at the top of every page isn't legal boilerplate — it reflects a genuine commitment to operating within the appropriate regulatory framework.
Our synthesis partner in Basel operates under continuous Current Good Manufacturing Practice (cGMP) oversight. The facility handles the full synthesis pipeline: solid-phase peptide synthesis (SPPS), purification by preparative HPLC, lyophilization, and quality release testing.
Basel was not a convenient choice — it was a deliberate one. Switzerland's pharmaceutical infrastructure, regulatory culture, and proximity to our primary testing partner (Eurofins in Hamburg, 6 hours by road) made it the right location for a supplier serious about quality.
From a two-person operation synthesizing BPC-157 in a Basel laboratory to 28,000+ researchers served across 40+ countries — in six years.
Zenova Bio synthesizes its first batch of BPC-157 analog at a partner facility in Basel. The first lot report is published publicly — a practice most vendors didn't offer. First 50 orders shipped within a week.
We formalise our relationship with Eurofins Scientific GmbH, establishing a per-lot testing contract covering identity, purity, potency, and endotoxin. Heavy metals screening added to the protocol later that year.
We transition from standard insulated mailers to pharmaceutical-grade phase-change cold-chain packaging with embedded temperature loggers. Every shipment now carries a verifiable temperature record from dispatch to delivery.
Nocturne, Lumen, and Reverie join the catalogue. The Lot Lookup tool launches, giving any customer instant access to full COA data by entering their vial's lot number. 10,000-researcher milestone reached.
Solace GLP-1 analog enters the catalogue. Partnership with Charles River Laboratories in Montreal enables additional Health Canada-aligned sterility testing for Canadian research customers.
Zenova Bio now serves researchers in over 40 countries with 14 active formulations. Six new compounds are in the R&D pipeline. The core commitment hasn't changed: synthesize well, verify everything, publish the proof.
A small team of chemists, researchers, and operations specialists who prefer doing the work to talking about it.
Every order ships with full lot documentation, cold-chain monitoring, and access to our research support team. If the science doesn't hold up, we'll make it right.